According to Rigshospitalet spin-out Cessatech, the company has initiated a Phase 3 trial of its CT001 sufentanil / ketamine nasal spray in children seen in the emergency department with moderate to severe pain. In July 2022, Cessatech announced plans for the 0205 trial of CT001 in adult patients following extraction of wisdom teeth, and the company reported results from that study in December 2023. The new trial, 0202, is expected to enroll 150 pediatric patients and to be completed by the end of this year.
Cessatech CEO Jes Trygved commented, “We are very pleased with the initiation of this important and final trial for CT001, and the company is now moving into a different stage with last study, great work and effort by all the people involved in the preparation and initiation of this trial, including the countries and sites involved. CT001 is getting closer to the market and its potential patients and the period ahead will be extremely interesting.”
Read the Cessatech press release.
